Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs TG Therapeutics Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.51 (market cap $157.51B), while TG Therapeutics Inc trades at $49.66 (market cap $7.64B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 20.6× TG Therapeutics Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BBVA | TGTX | |
|---|---|---|
Market Cap | $157.51B | $7.64B |
Sector | Financials | Health |
52-Week High | $28.50 | $59.06 |
52-Week Low | $17.96 | $26.94 |
Dividend Yield | 3.8% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.535, up 0.65% with bullish technical signals from moving averages. The bank reported strong Q2 2026 results with net profit rising 11.4% year-over-year and announced a $2.3 billion share buyback program. Revenue reached $39.42 billion in 2025 with net income margin of 26.13% and ROE of 18.5%. Analyst consensus leans bullish with 7 buy ratings among 13 analysts.
Outlook remains positive with improved profitability guidance and strategic leadership reshuffling. Key risks include ongoing antitrust investigations in Spain and potential economic divergence in core markets. The stock offers attractive valuation with P/E of 12.98x, though recent RSI levels suggest potential near-term consolidation.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
